John F. Sheridan - May 15, 2024 Form 4 Insider Report for TANDEM DIABETES CARE INC (TNDM)

Role
PRESIDENT & CEO, Director
Signature
/s/ Rachel Malina, Attorney-in-Fact for John F. Sheridan
Stock symbol
TNDM
Transactions as of
May 15, 2024
Transactions value $
-$487,300
Form type
4
Date filed
5/17/2024, 05:45 PM
Previous filing
Feb 29, 2024
Next filing
May 28, 2024

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction TNDM Common Stock Award $15.3K +978 +3.27% $15.64 30.9K May 15, 2024 Direct F1
transaction TNDM Common Stock Options Exercise $0 +792 +2.57% $0.00 31.7K May 15, 2024 Direct
transaction TNDM Common Stock Tax liability -$19K -402 -1.27% $47.37 31.3K May 15, 2024 Direct F2
transaction TNDM Common Stock Options Exercise $0 +2.24K +7.16% $0.00 33.5K May 15, 2024 Direct
transaction TNDM Common Stock Tax liability -$53.7K -1.13K -3.39% $47.37 32.4K May 15, 2024 Direct F2
transaction TNDM Common Stock Options Exercise $0 +21.9K +67.63% $0.00 54.2K May 15, 2024 Direct
transaction TNDM Common Stock Tax liability -$430K -9.07K -16.73% $47.37 45.2K May 15, 2024 Direct F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction TNDM Restricted Stock Unit Options Exercise $0 -792 -19.99% $0.00 3.17K May 15, 2024 Common Stock 792 Direct F3, F4, F5
transaction TNDM Restricted Stock Unit Options Exercise $0 -2.24K -20.01% $0.00 8.95K May 15, 2024 Common Stock 2.24K Direct F4, F6, F7
transaction TNDM Restricted Stock Unit Options Exercise $0 -21.9K -33.33% $0.00 43.8K May 15, 2024 Common Stock 21.9K Direct F8, F9, F10
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The reporting person is voluntarily reporting the acquisition of shares of common stock pursuant to the Tandem Diabetes Care, Inc. Amended and Restated 2013 Employee Stock Purchase Plan (ESPP), for the ESPP purchase period of November 16, 2023 through May 15, 2024. This transaction is also exempt under Rule 16b-3(c).
F2 Shares withheld by Tandem Diabetes Care, Inc. (the Company) to satisfy tax withholding requirements on vesting of restricted stock units (RSU). No shares were sold.
F3 Awarded on May 18, 2021 pursuant to the Tandem Diabetes Care, Inc. 2013 Stock Incentive Plan, as amended, and the agreements related thereto (the 2013 Plan).
F4 Each RSU represents a contingent right to receive either one share of common stock of the Issuer or cash in lieu thereof, at the Issuer's discretion, in accordance with the terms of the 2013 Plan.
F5 RSU vest as to twenty-five percent (25%) of the total number of shares subject to the RSU on 5/15/2022, and the remaining shares shall vest in twelve (12) equal quarterly installments thereafter.
F6 Awarded on May 25, 2022 pursuant to the 2013 Plan.
F7 RSU vest as to thirty-three percent (33%) of the total number of shares subject to the RSU on 5/15/2023, and the remaining shares shall vest in eight (8) equal quarterly installments thereafter.
F8 Awarded on May 25, 2023 pursuant to the Tandem Diabetes Care, Inc. 2023 Long-Term Incentive Plan (the 2023 Plan).
F9 Each RSU represents a contingent right to receive either one share of common stock of the Issuer or cash in lieu thereof, at the Issuer's discretion, in accordance with the terms of the 2023 Plan.
F10 RSU vest as to thirty-three percent (33%) of the total number of shares subject to the RSU on 5/15/2024, and the remaining shares shall vest in eight (8) equal quarterly installments thereafter.